Events

Cambridge Science Festival / Anne Phelan

AI Hype vs. Reality

Data science and AI have the potential to transform the discovery and development of medicines. However, there is a lot of hype surrounding AI. The session will cover: What has been achieved to date? What is realistic to expect from data science and AI in the next 5 to 10 years? How can data science experts manage expectations? How can pharma and tech better collaborate to realise the potential of data science and AI in healthcare?

How can data science experts manage expectations? How can pharma and tech better collaborate to realise the potential of data science and AI in healthcare? The interdisciplinary panel will be chaired by Gareth Mitchell, presenter from the BBC's Digital Planet.

Panellists include:

  • Dr Jim Weatherall (Vice President of Data Science & AI, R&D, AstraZeneca),
  • Professor Mihaela van der Schaar (Director, Cambridge Centre for AI in Medicine),
  • Anne Phelan (CSO, BenevolentAI)
  • Dr Junaid Bajwa (Chief Medical Scientist, Microsoft Research).

Register here →


Anne Phelan

Chief Scientific Officer

Anne is Chief Scientific Officer, Head of Preclinical Development and Site Head for the Benevolent Cambridge Laboratories. Anne is responsible for driving the early AI augmented discovery portfolio through Lead Optimisation to delivery of pre-clinical candidate drug molecules. Before joining BenevolentAI, Anne worked for Pharma (Pfizer) and Biotech (Mission Therapeutics), across a wide range of Therapeutic Areas including Fibrosis, Pain, A&R and Neurodegeneration. Anne holds a BSc and PhD in Genetics from the University of Liverpool, UK and has over 25 years experience from early discovery to late stage development

More Posts

You Might Also Like

News
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population
Apr 8, 2021
News
BenevolentAI named as one of Fierce Medtech’s Fierce 15 of 2020
BenevolentAI was selected as one of the most promising private companies in the industry by Fierce Medtech in its Fierce 15 2020 list.
Mar 8, 2021
Blog
Tech Nation Visa: the gateway to world-leading UK tech jobs
Drawing attention to the Tech Nation Visa, a great initiative that enables the brightest international talent to live and work in the UK.
Feb 19, 2021
News
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
A molecule designed and developed by BenevolentAI to treat mild to moderate Atopic Dermatitis has entered clinical trials.
Feb 11, 2021
News
BenevolentAI and AstraZeneca achieve collaboration milestone with novel AI-generated chronic kidney disease target
BenevolentAI and AstraZeneca hit collaboration milestone with an AI-generated CKD target from the partnership entering AstraZeneca’s portfolio.
Jan 27, 2021
News
ACTT-2 trial results published in the New England Journal of Medicine validate baricitinib’s efficacy in combination with remdesivir in hospitalised COVID-19 patients
Peer-reviewed data from the ACTT-2 further validate BenevolentAI’s hypothesis for baricitinib as a potential COVID-19 treatment.
Jan 15, 2021